Price
169.52
+3.52%52W Range
Market Cap
₹4,975.88 Cr
Traded: ₹124.03 Cr (2.49%) 0.0x
Free Float: ₹1,612.68 Cr (7.69% of FF traded)
Volume · 60D trend
73.24 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | +2.0% | -- | +19.0% | Accelerating |
| ROE | -- | +9.0% | +8.0% | -- | -- | Decelerating |
| Return | +20.0% | +5.0% | +29.0% | +78.0% | -- | Accelerating |
| Profit | -- | -- | +2.0% | -- | +68.0% | Accelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 756 | 619 | 580 | 568 | 552 | 528 | 523 | 526 | 502 | 504 | 520 | 545 | 563 | 587 | 523 | 541 |
| Expenses | 653 | 527 | 523 | 510 | 490 | 465 | 476 | 484 | 451 | 454 | 476 | 481 | 491 | 492 | 481 | 510 |
| Operating Profit | 103 | 92 | 57 | 57 | 62 | 63 | 47 | 42 | 51 | 50 | 44 | 64 | 73 | 95 | 43 | 32 |
| OPM % | 14.0% | 15.0% | 10.0% | 10.0% | 11.0% | 12.0% | 9.0% | 8.0% | 10.0% | 10.0% | 9.0% | 12.0% | 13.0% | 16.0% | 8.0% | 6.0% |
| Other Income | 8 | 2 | -6 | 7 | 7 | 5 | 4 | 6 | 7 | 8 | 8 | 7 | 7 | 9 | 7 | 5 |
| Interest | 4 | 3 | 4 | 3 | 4 | 4 | 4 | 4 | 2 | 3 | 4 | 4 | 4 | 5 | 5 | 4 |
| Depreciation | 21 | 20 | 20 | 20 | 20 | 19 | 19 | 18 | 17 | 16 | 16 | 16 | 14 | 12 | 12 | 11 |
| Profit Before Tax | 87 | 71 | 28 | 40 | 46 | 45 | 28 | 26 | 40 | 37 | 32 | 51 | 61 | 87 | 33 | 22 |
| Tax % | 26.0% | 25.0% | 25.0% | 26.0% | 25.0% | 30.0% | 26.0% | 26.0% | 24.0% | 26.0% | 28.0% | 26.0% | 25.0% | 26.0% | 28.0% | 28.0% |
| Net Profit | 64 | 53 | 21 | 30 | 34 | 31 | 21 | 19 | 30 | 28 | 23 | 38 | 46 | 65 | 24 | 16 |
| Exceptional Items | 0 | 0 | -11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -- |
| EPS (Rs) | 2.2 | 1.8 | 0.7 | 1.0 | 1.2 | 1.1 | 0.7 | 0.7 | 1.0 | 0.9 | 0.8 | 1.3 | 1.6 | 2.2 | 0.8 | 0.5 |
| Sales Growth (YoY) | 37.0% | 17.2% | 10.9% | 8.0% | 10.0% | 4.8% | 0.6% | -3.5% | -10.8% | -14.1% | -0.6% | 0.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 22.1% | 6.7% | 2.1% | 2.9% | 4.5% | 1.0% | -0.6% | 4.8% | -0.4% | -3.1% | -4.6% | -3.2% | -4.1% | 12.2% | -3.3% | -- |
| OP Growth (YoY) | 66.1% | 46.0% | 21.3% | 35.7% | 21.6% | 26.0% | 6.8% | -34.4% | -30.1% | -47.4% | 2.3% | 100.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 12.0% | 61.4% | 0.0% | -8.1% | -1.6% | 34.0% | 11.9% | -17.6% | 2.0% | 13.6% | -31.3% | -12.3% | -23.2% | 120.9% | 34.4% | -- |
| Profit Growth (YoY) | 90.0% | 69.0% | 41.0% | 56.0% | 13.0% | 14.0% | -11.0% | -49.0% | -35.0% | -57.0% | -3.0% | 138.0% | 32.0% | 118.0% | -- | -- |
| EPS Growth (YoY) | 88.8% | 69.2% | 0.0% | 56.9% | 13.7% | 13.8% | -11.4% | -49.6% | -34.6% | -57.5% | -2.5% | 138.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 21.0% | 158.6% | -31.4% | -12.1% | 8.4% | 52.9% | 7.7% | -36.3% | 8.5% | 19.0% | -38.8% | -17.3% | -29.4% | 172.8% | 50.0% | -- |
| OP Margin | 13.6% | 14.9% | 9.8% | 10.0% | 11.2% | 11.9% | 9.0% | 8.0% | 10.2% | 9.9% | 8.5% | 11.7% | 13.0% | 16.2% | 8.2% | 5.9% |
| Net Margin | 8.5% | 8.6% | 3.6% | 5.3% | 6.2% | 5.9% | 4.0% | 3.6% | 6.0% | 5.6% | 4.4% | 7.0% | 8.2% | 11.1% | 4.6% | 3.0% |
| Material Cost % | 63.0% | 60.0% | 66.0% | 65.0% | 66.0% | 66.0% | 68.0% | 68.0% | 67.0% | 64.0% | 68.0% | 65.0% | 65.0% | 64.0% | 71.0% | 74.0% |
| Employee Cost % | 9.0% | 11.0% | 10.0% | 11.0% | 10.0% | 10.0% | 10.0% | 11.0% | 11.0% | 10.0% | 9.0% | 9.0% | 10.0% | 7.0% | 8.0% | 7.0% |
| P/S | 1.97 | 2.12 | 1.45 | 0.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 29.64 | 35.79 | 27.88 | 18.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.77 | 2.74 | 1.84 | 1.22 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Earning Call Transcript
Submission of Newspaper Publication
Audio Recording of Analysts/Investors Call pertaining to the Financial Results Q1- FY2027
Investor Presentation
Communication to the Shareholders regarding AGM Notice ansd Annual Report for the Financial Year 2025-26
Submission of newspaper publication of unaudited Financial Results for the quarter ended 30th June 2026
Press Release- Financial Results for the quarter ended 30th June 2026
Submission of Unaudited Financial Results of the Company for the quarter ended 30th June 2026
Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter ended 30th June 2026
Copy of notice published in Newspapers
Submission of BRSR FY 2025-26
Submission of Integrated Annual Report for FY 2025-26
Schedule of analyst / investor conference call - Q1 FY27
Notice of 39th Annual General Meeting
Approval from NMPA,China foe Clopidogrel Bisulfate API
Certificate under Regulation 74(5) of SEBI(DP) Regulations,2018
Reaffirmation of Credit Rating
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for NM Merchantiles Ltd
Intimation of Closure of Trading Window
Submission of newspaper publication
Intimation regarding communication to shareholders relating to unclaimed dividend
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Earning call transcript
Schedule of Analyst/Investor Meeting
Audio Recording of Analysts/Investors Call pertaining to the Financial Results Q4 FY2026
Newspaper Publication
Investor Presentation
Fixed 39th Annual General Meeting of the Company and Book Closure of Register of Members
Outcome of the Board Meeting and submission of Audited Financial Results for the quarter and year ended 31st March 2026
Outcome of Board Meeting and submission of Audited Financial Results
Comments of Board of Directors
Annual Secretarial Compliance Report
Press Release: Financial Results for the quarter and year ended 31st March 2026
Schedule of analyst / investor conference call - Q4 FY26
IOL Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve the Audited ....
Disclosure under regulation 39 of Sexurities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations,2015
Submission of newspaper publication
Submission of Newspaper publication
Disclosure under Regulation 30
Compliance Certificate under Regulation 74
Intimation under Regulation 30
Intimation Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for NCVI Enterprises Ltd & PACs
Disclosure under SEBI (PIT) Regulations
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mayadevi Polycot Ltd & PACs
Disclosure under SEBI (PIT) Regulations
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for NCVI Enterprises Ltd & PACs
Disclosure under SEBI (PIT) Regulations
Disclosure under SEBI (PIT) Regulations
Disclosure under SEBI (PIT) Regulations
Annual Reports
16Credit Ratings
6Concalls
24Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Mar 2021
31 Mar 2021Dec 2020
31 Dec 2020Nov 2020
30 Nov 2020Held by ETFs
1 ETFs hold IOLCP · sorted by weight
Held by Mutual Funds
2 schemes hold IOLCP · sorted by weight